Prior studies suggest that increased urine albumin is associated with a heightened fracture risk in women, but results in men are unclear. We used data from MrOS, a prospective cohort study of community-dwelling men aged ≥65 years, to evaluate the association of increased urine albumin with subsequent fractures and annualized rate of hip bone loss. We calculated albumin/creatinine ratio (ACR) from urine collected at the 2003-05 visit. Subsequent clinical fractures were ascertained from triannual questionnaires and centrally adjudicated by review of radiographic reports. Total hip BMD was measured by DXA at the 2003-05 visit and again an average of 3.5 years later. We estimated risk of incident clinical fracture using Cox proportional hazards models, and annualized BMD change using ANCOVA. Of 2982 men with calculable ACR, 9.4% had ACR ≥30 mg/g (albuminuria) and 1.0% had ACR ≥300 mg/g (macroalbuminuria). During a mean of 8.7 years of follow-up, 20.0% of men had an incident clinical fracture. In multivariate-adjusted models, neither higher ACR quintile (p for trend 0.75) nor albuminuria (HR vs. no albuminuria, 0.89 [95%CI, 0.65-1.20]) was associated with increased risk of incident clinical fracture. Increased urine albumin had a borderline significant, multivariate-adjusted, positive association with rate of total hip bone loss when modeled in ACR quintiles (p=0.06), but not when modeled as albuminuria versus no albuminuria. Macroalbuminuria was associated with a higher rate of annualized hip bone loss compared to no albuminuria (-1.8% more annualized loss than in men with ACR <30 mg/g; p<0.001), but the limited prevalence of macroalbuminuria precluded reliable estimates of its fracture associations. In these community-dwelling older men, we found no association between urine albumin levels and risk of incident clinical fracture, but found a borderline significant, positive association with rate of hip bone loss.
Introduction
Chronic kidney disease (CKD) is defined as kidney dysfunction or kidney damage that persists for at least 3 months.(1) Multiple prospective studies have reported that kidney dysfunction, as estimated by reduced glomerular filtration rate (eGFR), is associated with increased hip bone loss, whether defined by cystatin C-based (eGFR cys ) or creatinine-based (eGFR cr ) equations. (2) (3) (4) (5) (6) In contrast, while numerous prospective studies have found an association of reduced eGFR cys with increased risk of hip fracture, most have not identified an association of eGFR cr with fracture risk. (2) (3) (4) (7) (8) (9) (10) (11) The excessive excretion of urinary albumin is an indicator of kidney microvascular damage. Because increasing evidence suggests that the microvasculature is important in skeletal health, (12) it has been proposed that increased excretion of urinary albumin may be a marker of co-existing microvascular abnormalities in bone, and therefore may predict adverse skeletal outcomes. (13) A few large cross-sectional studies have reported that increased urine albumin is associated with lower BMD, (13) (14) (15) (16) but prospective analyses appear inconclusive and limited to small studies in narrow populations. (17, 18) Prospective studies have reported a positive association between urine albumin and risk of nonvertebral fractures, with some, (13, 15) but not all, (19, 20) reporting that the increased risk was present only in women and not men. In part because these studies included relatively few fracture events in men, it is unclear if these findings indicate a true gender difference.
In order to elucidate the prospective association of urine albumin excretion with skeletal health in older men, the present study examined whether increased urine albumin is independently associated with hip bone loss and incident fractures in the large, multi-site cohort of community-dwelling older men enrolled in the Osteoporotic Fractures in Men (MrOS) study.
Materials and Methods

Participants
From March 2000 to April 2002, 5994 community-dwelling men aged ≥65 years were recruited to participate in the MrOS Study, a prospective cohort study at six US sites: Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Monongahela Valley near Pittsburgh, PA; Portland, OR; and San Diego, CA. MrOS exclusion criteria included inability to walk without assistance from another person and a history of bilateral hip replacement. The institutional review boards at all participating centers approved the study protocol, and written informed consent was obtained from all participants included in the study. Details of the MrOS study design and recruitment have been described elsewhere. (21, 22) From December 2003 to March 2005, active MrOS participants were invited to participate in the ancillary MrOS Sleep Study. Among the original 5994 MrOS enrollees, 344 had died and 36 had terminated prior to MrOS Sleep Study recruitment, and 150 were excluded from the Sleep Study because they were receiving positive-pressure treatment for sleep apnea or snoring (Figure) . Among the remaining 5464 men, 3135 (57%) agreed to participate in the Sleep Study (exceeding the recruitment goal of 3000 men). Of these Sleep Study participants, spot urine collection was performed and urinary albumin/creatinine ratio (ACR) measurements were available in 2982 men, forming the incident fracture analytic cohort (Figure) . Among the 2982 men with available ACR measures, 2365 had adequate measures of total hip BMD (g/cm 2 ) at both MrOS Sleep baseline and MrOS visit 3 (March 2007 to March 2009), forming our hip bone loss analytic cohort.
Urine albumin and creatinine assays
First morning urine voids were collected at the MrOS Sleep Study baseline visit, following which they were stored at -80°C. From these samples, urine albumin and creatinine were measured using a Roche Modular P chemistry analyzer (Roche Diagnostics). The lower detectable limit for urine albumin was 1.0 mg/L. Inter-assay CV for urine albumin was 10.4% at 19.2 mg/L and 2.1% at 109.6 mg/L. Inter-assay CV for urine creatinine was 1.5% at 96.6 mg/dL and 4.3% at 18.4 mg/dL. The ACR in mg albumin/g creatinine was calculated by dividing the urine albumin concentration in mg/L by the urine creatinine concentration in g/L. Albuminuria was considered present if ACR was ≥30 mg/g, with microalbuminuria defined as ACR 30-299 mg/g and macroalbuminuria defined as ACR ≥300 mg/g.(23)
Ascertainment of incident clinical fractures
Incident clinical fractures (both nonvertebral and clinical vertebral) were initially identified from participant (or, in the event of death, participant's family or contacts) responses to triannual contacts. More than 99% of triannual contacts were completed through a mean of 8.7 +/-3.4 years of follow-up. Incident nonvertebral fractures were centrally confirmed by study physician review of community radiographic reports. Incident clinical vertebral fractures were defined by both 1) presence of symptoms suggestive of vertebral fracture (e.g., back pain) that prompted the participant to seek medical attention in the community and 2) a community imaging study (e.g., radiograph, computed tomography) centrally reviewed by a masked study physician that showed a ≥1 increase in semiquantitative (SQ) grade(24) compared to the same thoracic or lumbar vertebrae on the baseline study radiograph. Incident major osteoporotic fractures were defined as any incident hip, wrist, humerus or clinical vertebral fracture.
Measurement of bone loss
Total hip bone mineral density (BMD) was measured in the right hip at the MrOS Sleep Study baseline examination and subsequent MrOS visit 3 using dual-energy X-ray absorptiometry (DXA) (QDR-4500W; Hologic Inc., Waltham, MA) unless the participant reported a right hip replacement or metal objects in the right leg, in which case the left hip was measured. MrOS DXA quality assurance measures have been detailed previously. (22) Based on common phantoms measured at all clinics, variability across clinics was within acceptable limits, and cross-calibration correction factors were not required. To monitor longitudinal changes, each clinic scanned hip phantoms throughout the study, and correction factors for longitudinal changes were applied to participant data as appropriate. Precision of hip DXA scans was 1-2%.
Other measurements
Variables previously associated with incident nonspine fracture (25) or albuminuria (26, 27) and collected at MrOS Sleep Study baseline included: birth date, race, self-reported fracture at age ≥50, falls in the past year, depressed mood most or all the time, and physician diagnosis of osteoporosis, hypothyroidism, diabetes, or cardiovascular disease (stroke, congestive heart failure, or hypertension). Physical activity was measured using the Physical Activity Scale for the Elderly (PASE).(28) Functional status was measured by the number of five instrumental activities of daily living (IADLs) with which participants reported difficulty. Depressed mood was defined as a score of ≥6 on the Geriatric Depression Scale (GDS).(29) A medication inventory was used to classify medications used within the preceding 30 days into categories by their ingredients, including thyroid hormone, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, loop diuretics, thiazide diuretics, other antihypertensives, diabetes medications, antidepressants, and osteoporosis medications. (30) In-clinic measures included height (stadiometer) and weight (balance beam or digital scale), from which body mass index (BMI) was calculated as kilograms per square meter. Participants were timed walking 6 meters while taking <2 deviations outside a 20 cm narrow path. Grip strength was measured by a Jamar dynamometer (Sammons Preston Rolyan, Bolingbrook, IL, USA).(31) Serum cystatin C concentrations were determined using a BN100 nephelometer (Dade Behring Inc., Deerfield, IL) using a particle-enhanced immunonepholometric assay(32) (assay range 0.23-8.00 mg/L with inter-assay coefficient of variation [CV] of 4.0% at a level of 0.71 mg/L and 3.1% at a level of 1.75 mg/L [mean inter-assay CV 3.7%]) and then converted to standardized values traceable to a certified reference material.(33) Kidney function then was calculated using the cystatin-derived estimated glomerular filtration rate (eGFR cys ) (CKD-EPI equation). (34) 
Statistical Analysis
Differences in characteristics at the baseline of the main MrOS study were compared between the 2982 men included in the incident fracture analytic cohort and the 2320 men still enrolled in the main MrOS study at the time the Sleep Study began but who were not included in the analytic cohort using chi-square tests, t-tests and Wilcoxon rank-sum tests as appropriate (Supplemental Table 1 ). In participants with available ACR measures, tests for a linear trend adjusted for age across quintiles were performed by including the predictor (ordinal variable, five levels) as an independent variable in linear regression for continuous variables and logistic regression for categorical variables ( Table 1 ).
Time to incident fracture was calculated as the interval from the Sleep Study baseline visit (2003 to 2005) to the earliest date of first incident fracture, death, loss to follow-up, or end of fracture follow-up on January 30th, 2016. Cox proportional hazards models were used to estimate the risk of incident clinical fracture, and incident major osteoporotic fracture, first across ACR quintiles, using men with no measurable urinary albumin as the reference category, then in men with versus without albuminuria (ACR ≥30mg/g vs. <30 mg/g), and last, per 1 SD of log-transformed ACR, and in men with ACR ≥300 mg/g and 30-299 mg/g vs. <30 mg/g. Results were expressed as hazard ratios (HR) with 95% confidence intervals (CI).
Change in total hip BMD between the MrOS Sleep Study baseline and MrOS visit 3 was assessed using ANCOVA, both across ACR quintiles, using men with no measurable urinary albumin as the reference category, and in men with versus without albuminuria. Results were expressed as the annualized percent change in total hip BMD between these visits with 95% CI, with differences between ACR quintiles and in men with ACR ≥30 mg/g vs. <30 mg/g tested using linear trend tests and chi-square tests, respectively. Again, sensitivity analyses were performed, comparing results in men with ACR ≥300 mg/g and 30-299 mg/g vs. <30 mg/g. Initial fracture and BMD change models were adjusted for age, race and clinic site (model 1). From among variables previously associated with incident nonspine fracture (25) or albuminuria, (26, 27) those significantly associated (p<0.05) with risk of incident clinical fracture in a model including variables for ACR (continuous), age, race and clinic site, were additionally included in all multivariate-adjusted fracture and BMD change models (model 2). Next, models were additionally adjusted for eGFR cys (model 3) and further adjusted for PASE score and walk speed (model 4). Last, to evaluate whether risk for fracture conferred by urinary albumin differed in the shorter term, we truncated model 3 multivariate-adjusted analyses after five years of follow-up (model 5).
All analyses were performed with SAS (version 9.3, SAS Institute, Cary, NC). 
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Results
Study population
Among men who remained enrolled in the main MrOS Study at the time of the Sleep Study baseline, compared to those not included in the incident fracture analytic cohort, those in the incident fracture analytic cohort had been healthier at the main MrOS Study baseline. They had been younger, had less difficulty with ADLs, more physically active, walked faster, and had a stronger grip and a higher total hip BMD (Supplemental Table 1 ).
Among the 2982 participants in the incident fracture analytic cohort, mean age at the MrOS Sleep Study baseline visit was 76.4 years (SD 5.5), and 90.6% of men were Caucasian (Table 1) . Seventy-two percent of men had eGFR cys ≥60 mL/min per 1.73 m 2 , 20.0% had eGFR cys of 45 to <60, 6.9% had eGFR cys of 30 to <45, and 1.2% had eGFR cys of <30. Median ACR was 2.7 mg/g, 9.4% of men had ACR ≥30 mg/g, 1.0% of men had ACR ≥300 mg/g, and cutpoints for ACR quintiles were 0-0, 0.26-1.88, 1.88-3.69, 3.69-10.55, and 10.56-2364.15 mg/g. Men with higher levels of ACR were older than those with lower ACR. After adjustment for age, those with higher ACR had more difficulty with IADLs, were less physically active, walked more slowly, had weaker grip strength, were more likely to have fallen in the past year, had a higher prevalence of cardiovascular disease and diabetes, had a higher prevalence of ACE inhibitor, angiotensin receptor blocker and loop diuretic use, and had a lower eGFR cys . Osteoporosis medication use was uncommon.
Among men in the incident fracture analytic cohort with hip BMD measured at the Sleep Study baseline, those with subsequent hip BMD measures at MrOS visit 3 (i.e. those included in the hip bone loss analytic cohort), had previously experienced less hip bone loss between the main MrOS Study baseline and the Sleep Study baseline than did those without visit 3 hip BMD measures (-2.28% vs. -1.13% mean loss, over a mean interval of 3.4 +/-0.5 years; p<0.0001).
Incident fractures
During a mean of 8.7 +/-3.4 SD years of fracture follow-up, 596 (20.0%) men had an incident clinical fracture and 286 (9.6%) had an incident major osteoporotic fracture. These included 124 men (4.2%) with an incident hip fracture, 93 (3.1%) with an incident clinical vertebral fracture, and 442 (14.8%) with an incident nonhip nonvertebral fracture. When compared to men with ACR <30 mg/g, the relative hazard of incident clinical fracture in men with albuminuria was 0.96 (95% CI, 0.72-1.28) after adjustment for age, race and study site ( Table 2) . Results were similar after further adjustment for history of fracture after age 50, history of fall in the past year, total difficulty with IADLs, loop diuretic use, osteoporosis drug use, antidepressant use, GDS score ≥6, grip strength, and eGFR cys (HR, 0.89 [95%CI, 0.65-1.20]). Analyses of the risk of incident clinical fractures across ACR quintiles also was not statistically significant (Table 2) . Similarly, neither albuminuria nor higher ACR quintile was associated with increased risk of incident major osteoporotic fracture across all models ( Tables 2 and 3 ). Results were similar after adjustment for additional potential confounders and risks appeared smaller in magnitude when analyses were limited to five years of follow-up (Model 5 in Tables 2 and 3) . Although, risk of incident clinical fracture appeared possibly higher in men with ACR ≥300 mg/g than in those with ACR <30 mg/g (Tables 2 and 3) , there were too few men with macroalbuminuria for the estimated fracture risk in this group to be considered reliable (Of the 29 men with macroalbuminuria, 7 had an incident clinical fracture).
Total hip bone loss
Among the 2365 participants with available ACR measures and repeat total hip BMD measures, mean annualized rate of total hip BMD loss was -0.40% (SD 1.11%). Men with albuminuria had a significantly higher annualized rate of total hip BMD loss than those without albuminuria in analyses adjusted for age, race and study site (-0.21% difference in annualized rate of loss, p=0.02) ( Table 4 ). This difference was attenuated after further adjustment for history of fracture after age 50, history of fall in the past year, total difficulty with IADLs, loop diuretic use, osteoporosis drug use, antidepressant use, GDS score ≥6, and grip strength (-0.17% difference in annualized rate of loss, p=0.045). After additional adjustment for eGFR cys , PASE score and walk speed, the higher annualized rate of total hip BMD loss in men with albuminuria was further attenuated and no longer statistically significant (Table 4) . Similarly, in analyses of annualized rate of total hip BMD loss across ACR quintiles, there was a significant trend for a higher rate of bone loss in the highest quintiles in the model adjusted for age, race and study site, but this trend was only borderline significant in the more fully adjusted models (Table 4 ).
Discussion
In this cohort of community-dwelling older men, we found no statistically significant association of higher urine albumin with risk of incident clinical fracture or incident major osteoporotic fracture. Results were consistent in analyses modeling urine albumin in ACR quintiles including within the normoalbuminuria range, as ACR ≥30 mg/g versus <30 mg/g, or as log-transformed ACR, and in both minimally and more fully adjusted models. Although risk of incident fracture appeared possibly higher in men with ACR ≥300 mg/g than in those with ACR <30 mg/g, there were too few men with this higher level of albuminuria for their fracture risk estimate to be considered reliable. We also found that higher urine albumin was associated with a very small, though statistically significant increase in the rate of annualized hip bone loss in analyses modeling urine albumin in ACR quintiles or as ACR ≥30 mg/g versus <30 mg/g. These associations became attenuated after adjustment for multiple potential confounders and were only borderline statistically significant after further adjustment by eGFRcys, PASE score and walk speed. By comparison, when compared to men with ACR <30 mg/g, those with ACR ≥300 mg/g had a nearly 2% greater annualized rate of hip bone loss.
Three prior studies that included both men and women (range 41-50% men) reported that a continuous measure of urine albumin, either a doubling (13, 19) or SD increase (15) in log transformed ACR, was associated with a statistically significantly increased risk of incident (20) Two of these studies reported that higher urine albumin was associated with a statistically significant increase in incident fracture risk in women but not in men, (13, 15 ) though they did not directly compare the results between sexes. Two other studies reported that there was no significant interaction by sex, did not report their statistical power to detect a significant interaction, and did not report genderstratified results. (19, 20) The current study supports the evidence from earlier studies that suggests that there is no association between urine albumin levels and fracture risk in men, at least in those with ACR <300 mg/g. The current study has inadequate statistical power to determine whether there is a significant association between macroalbuminuria and fracture and no prior study has examined the association of this higher level of albuminuria with fracture in men.
Two recent studies evaluated albuminuria and repeat BMD measures. One, conducted in 90 participants with HIV on stable antiretroviral treatment, reported that baseline ACR was not significantly associated with change in femoral neck BMD over a mean of 40.8 months. (17) The second, conducted in 242 participants with HIV who were switching antiretroviral treatments, reported that both ACR and hip and spine BMD improved over 48 weeks, but did not directly assess the association of baseline or change in ACR with change in BMD. (18) The current study appears to be the first to evaluate the association of albuminuria with subsequent change in BMD in a large, more population representative cohort. The MrOS study results add to the limited prior evidence that suggests that albuminuria increases risk of BMD loss.(13-15) Moreover, because evaluation of change in total hip BMD required participants to return for follow-up DXA measures, and the men who did not return for repeat BMD testing appeared at greatest risk for accelerated hip bone loss, our results may have underestimated the true effect of albuminuria on rates of hip bone loss.
This study has several strengths, including its enrollment of community-dwelling older men not selected on the basis of kidney disease or risk for bone loss or fracture. Additional strengths include its large size, prospective design, repeat BMD measurements, and adjudication of fracture outcomes. Further, analyses were adjusted for multiple potential confounders, including eGFR cys . This allowed us to analyze the association of albuminuria on bone loss independent of the traditional mechanisms through which CKD patients are believed to develop bone disease, such as secondary hyperparathyroidism, with the caveat that few study participants had eGFR cys <30, when this complication becomes more prevalent.
Limitations of the study include its reliance on a single measurement to define albuminuria, as is common in epidemiological studies. Because a substantial portion of individuals with microalbuminuria spontaneously revert to normal urine albumin levels, (35, 36) our analyses may have underestimated the association of persistent albuminuria (i.e., for >3 months)(1) with bone loss and fracture risk. Second, our cohort included only a small number of participants with macroalbuminuria. Though our data suggested that older men with ACR ≥300 mg/g may have clinically meaningful increases in fracture risk and hip bone loss, our sample size for this group was too small to draw definitive conclusions, particularly for fracture outcomes. Third, because men at greatest risk for accelerated hip bone loss were least likely to return for repeat BMD testing, our results may have underestimated the true effect of albuminuria on rate of hip bone loss. Fourth, the absence of women in the MrOS cohort precluded analyses to directly compare the association of albuminuria with fracture and bone loss between men and women, which has been suggested to be different by some, but not all prior studies. Without inclusion of women, we also were unable to explore reasons why an association of albuminuria with fracture and bone loss might exist in women but not men, including whether this may be explained in part by sex differences in the urine albumin cutpoints used to define macroalbuminuria and in the prevalence of macroalbuminuria. Though older men have a higher mortality risk than women and may be more likely to die before experiencing fracture, particularly among those with higher levels of albuminuria, which has a well established association with increased mortality, this should not affect estimates of fracture risk associated with urine albumin among those alive and still at risk for fracture. (37, 38) Fifth, MrOS participants were largely healthy, community-dwelling older men, and those who were included in the current analyses were healthier still, so findings may have limited generalizability to the entire population of older men. Last, some prior studies have theorized that the association of albuminuria with fracture may reflect a systemic adverse effect of microvascular disease on bone health. (13, 20, 39) As the MrOS study did not directly measure bone microvascular health, we were unable to investigate this possible mechanism.
In conclusion, we found no independent association of a one-time measure of urine albumin with risk of incident fracture in older men. We found that increased urine albumin levels were associated with a very small, though significant increase in the rate of annualized hip bone loss. Though analyses in the small subset of men with macroalbuminuria suggested that they may have a clinically meaningful greater rate of hip bone loss, and possibly a higher fracture rate, there were too few men with macroalbuminuria for these fracture results to be considered reliable. Future studies should investigate the association of persistent albuminuria with risk of fracture and rate of bone loss, and should include and compare the results in both men and women. Pooling of data from multiple studies or use of linked renal and administrative databases may be necessary to better evaluate these associations in individuals with macroalbuminuria.
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